Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
11.96 USD | -0.25% | -2.95% | -44.51% |
Apr. 25 | Truist Securities Cuts Sage Therapeutics' Price Target to $18 From $22, Hold Rating Maintained | MT |
Apr. 25 | Transcript : Sage Therapeutics, Inc., Q1 2024 Earnings Call, Apr 25, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.51% | 722M | |
+5.68% | 111B | |
+11.60% | 106B | |
-12.71% | 22.24B | |
-0.20% | 21.25B | |
-4.97% | 18.97B | |
-35.21% | 18.52B | |
-11.13% | 16.81B | |
+38.02% | 12.54B | |
-24.86% | 8.09B |
- Stock Market
- Equities
- SAGE Stock
- News Sage Therapeutics, Inc.
- Canaccord Genuity Downgrades Sage Therapeutics to Hold From Buy, Cuts Price Target to $21 From $64